Case report: progressive familial intrahepatic cholestasis type 3 with compound heterozygous ABCB4 variants diagnosed 15 years after liver transplantation
Open Access
- 30 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medical Genetics
- Vol. 21 (1), 1-6
- https://doi.org/10.1186/s12881-020-01173-0
Abstract
Progressive familial intrahepatic cholestasis (PFIC) type 3 is an autosomal recessive disorder arising from mutations in the ATP-binding cassette subfamily B member 4 (ABCB4) gene. This gene encodes multidrug resistance protein-3 (MDR3) that acts as a hepatocanalicular floppase that transports phosphatidylcholine from the inner to the outer canalicular membrane. In the absence of phosphatidylcholine, the detergent activity of bile salts is amplified and this leads to cholangiopathy, bile duct loss and biliary cirrhosis. Patients usually present in infancy or childhood and often progress to end-stage liver disease before adulthood. We report a 32-year-old female who required cadaveric liver transplantation at the age of 17 for cryptogenic cirrhosis. When the patient developed chronic ductopenia in the allograft 15 years later, we hypothesized that the patient’s original disease was due to a deficiency of a biliary transport protein and the ductopenia could be explained by an autoimmune response to neoantigen that was not previously encountered by the immune system. We therefore performed genetic analyses and immunohistochemistry of the native liver, which led to a diagnosis of PFIC3. However, there was no evidence of humoral immune response to the MDR3 and therefore, we assumed that the ductopenia observed in the allograft was likely due to chronic rejection rather than autoimmune disease in the allograft. Teenage patients referred for liver transplantation with cryptogenic liver disease should undergo work up for PFIC3. An accurate diagnosis of PFIC 3 is key for optimal management, therapeutic intervention, and avoidance of complications before the onset of end-stage liver disease.Keywords
Funding Information
- Canadian Institutes of Health Research
- Canadian Liver Foundation
This publication has 26 references indexed in Scilit:
- Functional rescue of an ABCB11 mutant by ivacaftor: A new targeted pharmacotherapy approach in bile salt export pump deficiencyLiver International, 2020
- Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse modelNature Communications, 2019
- Functional characterization of ABCB4 mutations found in progressive familial intrahepatic cholestasis type 3Scientific Reports, 2016
- New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyondJournal of Hepatology, 2015
- Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4‐phenylbutyrateJournal of Hepatology, 2015
- Presentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to TreatmentPediatric Gastroenterology, Hepatology & Nutrition, 2015
- Cholestatic Liver Diseases from Child to Adult: The Diversity of MDR3 DiseaseZeitschrift für Gastroenterologie, 2011
- Progressive familial intrahepatic cholestasis.2010
- Progressive familial intrahepatic cholestasisOrphanet Journal of Rare Diseases, 2009
- A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasisNature Genetics, 1998